https://orcid.org/0000-0003-4599-4291
Graphical abstract
Transparency
Declaration of funding
This work was produced by representatives of Open Pharma. Open Pharma is a multi-sponsor collaboration facilitated by Oxford PharmaGenesis Ltd and receives sponsorship funding from Alexion Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, ER Squibb & Sons LLC, F. Hoffmann-La Roche AG, Galápagos NV, Gilead Sciences, Inc., GlaxoSmithKline Biologicals SA, Ipsen Biopharm Ltd, Janssen Global Services LLC, John Wiley & Sons Ltd, Novartis Pharma AG, Novo Nordisk A/S, Pfizer Inc., Takeda Development Center Americas, Inc. and UCB Biopharma SRL.
Declaration of financial/other relationships
AR and TK are employees of Oxford PharmaGenesis Ltd. SB is an employee of Galápagos NV and holds stock options. LF is an employee of UCB Pharma and may hold stock or stock options. WG was an employee and shareholder of Ipsen at the time of infographic development and is now an employee of Bristol Myers Squibb Ltd. REO is an employee and shareholder of F. Hoffmann-La Roche Ltd. AW is an employee and shareholder of Pfizer Inc. CW is an employee and Director of Oxford PharmaGenesis Ltd, and a Director and shareholder of Oxford PharmaGenesis Holdings Ltd. He is also a Director of Oxford Health Policy Forum CIC, Trustee of the Friends of the National Library of Medicine, and co-founder of Open Pharma.
Author contributions
All authors contributed to the drafting, development, and final approval of the work equally; all authors agree to be accountable for all aspects of the work. This work represents the opinions of the authors and not of their respective affiliations.
Acknowledgements
Graphic design assistance was provided by Jen Skelton and editorial assistance was provided by Velissaria Vanna, both of Oxford PharmaGenesis Ltd. No further writing assistance is to be declared.